4-Star Stocks Poised to Pop: Pfizer

Before you go, we thought you'd like these...
Before you go close icon

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug behemoth Pfizer (NYS: PFE) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Pfizer's business and see what CAPS investors are saying about the stock right now.

Pfizer facts

Founded (founded)New York (1849)
Market Cap$178.2 billion
IndustryPharmaceuticals
Trailing-12-Month Revenue$66.3 billion
ManagementChairman/CEO Ian Read
CFO Frank D'Amelio
Return on Equity (average, past 3 years)9.8%
Cash/Debt$24.0 billion / $39.1 billion
Dividend Yield3.7%
CompetitorsMerck
Novartis
Sanofi

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 90% of the 6,086 members who have rated Pfizer believe the stock will outperform the S&P 500 going forward.  

Just two days ago, one of those Fools, Ghengis11, succinctly summed up the Pfizer bull case for our community:

[C]onsistently successful with a lot of options in the pipeline. Lipitor, Celebrex and of course, Viagra. When was the last time a commercial came on and we remembered other male medications, but mention Viagra, and everyone around knows what you're talking about. [Pfizer] is the consistent home run hit.

If you want market-beating returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its four-star rating, Pfizer may not be your top choice.

If that's the case, we've compiled a special free report for investors called "The 3 Dow Stocks Dividend Investors Need," which uncovers a few other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow theTrackPoisedToCAPS account.

The article 4-Star Stocks Poised to Pop: Pfizer originally appeared on Fool.com.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners